

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Desmond John BEST et al.

International App. No.: PCT/EP2003/011650

International Filing Date: October 20, 2003

Title: *Bicyclic Benzamide Compounds as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP2003/011650 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

Express Mail Label No.: EV332065615US

Date of Mailing: 4/21/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


Patty Wilson
Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 21 April 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	SERIAL NO.	To be assigned
	FILING DATE	Concurrently herewith
	APPLICANT	Desmond John BEST
	GROUP	
	EXAMINER	
ATTORNEY DOCKET NO.		P33128USw

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page _____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
1.	WO02076925	10/3/2002	PCT			
2.	WO0224695	3/28/2002	PCT			
3.	WO0212190	2/14/2002	PCT			
4.	WO0006254	2/10/2000	PCT			
5.	WO0123374	4/5/2001	PCT			
6.	WO01066520	9/13/2001	PCT			
7.	WO02094788 ✓	11/28/2002	PCT			
8.	WO9850363	11/12/1998	PCT			
9.	WO9850364	11/12/1998	PCT			
10.	WO9840385	9/17/1998	PCT			
11.	WO0166534	9/13/2001	PCT			
12.	WO9534540	12/21/1995	PCT			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

13.	ADCOCK et al., "Substituent Effects of ¹⁹ F Nuclear Magnetic Resonance: Polar and π -Electron Effects", Aust. J. Chem 29:2571-2581 (1976).
14.	AUSTIN et al., "Novel 2,3,4,5-Tetrahydro-1H-3-benzazepines with High Affinity and Selectivity for the Dopamine ₃ Receptor", Bioorg Med Chem Lett 10:2553-2555 (2000).
15.	AUSTIN et al., "Design and Synthesis of Novel 2,3-Dihydro-1H-isoindoles with High Affinity and Selectivity for the Dopamine D ₃ Receptor, " Bioorg Med Chem Lett 11:685-688 (2001).
16.	FRANKEL, Chemische Berichte Vol. 33 pp. 2811 (1900).
17.	GIOVANNINI et al., "Effects of histamine H ₃ receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).
18.	LEURS et al., "Therapeutic potential of histamine H ₃ receptor agonists and antagonists," TiPS 19:177-183 (May 1998).
19.	LOVENBERG et al., "Cloning and Funcnional Expression of the Human Histamine H ₃ Receptor," Molecular Pharmacology 55:1101-1107 (1999).
20.	ONODERA and WATANABE, "Histamine H ₃ Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
21.	RICE et al., "Synthesis of Fluorinated Derivatives of Benzo[k]fluoranthene and indeno[1,2,3-cd]pyrene and 8,9-Dihydro-8,9-epoxybenzo[k]fluoranthene," J. Org. Chem 53:1775-1779 (1988).
22.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H ₃ heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).
23.	STOKKER, "Preparation of 1,2,3,4-Tetrahydroisoquinolines Lacking Electron Donating Groups - An Intramolecular Cyclization Complementary to the Pictet-Spengler Reaction," Tetrahedron Letters 37(31):5453-5456 (1996).
24.	WALSH et al., "Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and Structurally Related Compounds," J. Med. Chem 32:105-118 (1989).
25.	WEINSTOCK et al., "Synthesis and Renal Vasodilator Activity of Some Dopamine Agonist 1-Aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: Halogen and Methyl Analogues of Fenoldopam," J. Med. Chem 29:2315-2325 (1986).

Continue on page _____

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.